Cargando…

Tumor necrosis factor‐alpha stimulated gene‐6: A biomarker reflecting disease activity in rheumatoid arthritis

BACKGROUND: To explore the serum tumor necrosis factor‐alpha stimulated gene‐6 (TSG‐6) level and its association with disease activity in rheumatoid arthritis (RA) patients. METHODS: We recruited 176 RA patients, 178 non‐RA patients (lupus erythematosus, osteoarthritis, ulcerative colitis, ankylosin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Tingting, Liu, Yuhan, Li, Xu, Li, Xiaohang, Liu, Yanzhao, Wang, Qunxia, Huang, Jiayi, Yu, Jianlin, Wu, Yang, Chen, Simei, Zeng, Tingting, Tan, Liming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9102767/ https://www.ncbi.nlm.nih.gov/pubmed/35353944 http://dx.doi.org/10.1002/jcla.24395

Ejemplares similares

TRAP1 Shows Clinical Significance in the Early Diagnosis of Small Cell Lung Cancer
por: Li, Xiaohang, et al.
Publicado: (2021)

Application of collagen triple helix repeat containing‐1 and mitotic spindle apparatus antibody in small cell lung cancer diagnosis
por: Liu, Yuhan, et al.
Publicado: (2022)

Serum Tumor Necrosis Factor-Alpha as a Competent Biomarker for Evaluation of Disease Activity in Early Rheumatoid Arthritis
por: Inam Illahi, Mehreen, et al.
Publicado: (2021)

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
por: Alonso-Ruiz, Alberto, et al.
Publicado: (2008)

Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
por: Leboime, Ariane, et al.
Publicado: (2009)

Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
por: Nair, Shaalina, et al.
Publicado: (2022)

Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.
por: Fröde, Tânia Silvia, et al.
Publicado: (2002)

Anti-tumour necrosis factor alpha treatment in patients affected by rheumatoid arthritis with anti-Ro/SSA antibodies
por: Cavazzana, I, et al.
Publicado: (2005)

Effect of Exposure to Tobacco Smoke on Response to Anti-Tumor Necrosis Factor-Alpha Treatment in Patients with Rheumatoid Arthritis
por: KARAAHMET, Ozgur Zeliha, et al.
Publicado: (2016)

Obesity and Remission Rates in Japanese Patients With Rheumatoid Arthritis Requiring Anti-Tumor Necrosis Factor Alpha Therapy
por: YAMAZAKI, Kenji, et al.
Publicado: (2020)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Contribution for new genetic markers of rheumatoid arthritis activity and severity: sequencing of the tumor necrosis factor-alpha gene promoter
por: Fonseca, João Eurico, et al.
Publicado: (2007)

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

Therapeutic inhibition of tumour necrosis factor alpha reduces oligoclonality in the selected T-cell receptor BV families in rheumatoid arthritis
por: Pierer, M, et al.
Publicado: (2003)

Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis
por: Kawabata, Tomoko, et al.
Publicado: (2010)

Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis
por: Stavropoulos-Kalinoglou, Antonios, et al.
Publicado: (2012)

Association of single nucleotide polymorphism at position −308 of the tumor necrosis factor-alpha gene with ankylosing spondylitis and rheumatoid arthritis
por: Manolova, Irena, et al.
Publicado: (2014)

Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking
por: Bai, Liang Liang, et al.
Publicado: (2021)

High Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis
por: Elalouf, Ofir, et al.
Publicado: (2021)

Recombinant interferon alpha 2b in rheumatoid arthritis: good antigen for rheumatoid arthritis antibodies
por: Ali Khan, Wahid
Publicado: (2018)

Synovial tissue transcriptomes of long-standing rheumatoid arthritis are dominated by activated macrophages that reflect microbial stimulation
por: Smiljanovic, Biljana, et al.
Publicado: (2020)

T cell contact-mediated induction of tumor necrosis factor alpha in peripheral blood monocytes is inhibited by autologous serum in rheumatoid arthritis
por: Wagner, U, et al.
Publicado: (2003)

Increased Autophagy Enhances the Resistance to Tumor Necrosis Factor-Alpha Treatment in Rheumatoid Arthritis Human Fibroblast-Like Synovial Cell
por: Dai, Yujie, et al.
Publicado: (2018)

Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature
por: Park, Su-Kyung, et al.
Publicado: (2017)

Clinical significance of high‐mobility group box‐1 (HMGB1) in subjects with type 2 diabetes mellitus (T2DM) combined with chronic obstructive pulmonary disease (COPD)
por: Huang, Jiayi, et al.
Publicado: (2019)

Clinical significance of BPI‐ANCA detecting in COPD patients with Pseudomonas aeruginosa colonization
por: Tian, Yongjian, et al.
Publicado: (2019)

The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis
por: Wu, Jianhong, et al.
Publicado: (2020)

CD6 and Syntaxin Binding Protein 6 Variants and Response to Tumor Necrosis Factor Alpha Inhibitors in Danish Patients with Rheumatoid Arthritis
por: Krintel, Sophine B., et al.
Publicado: (2012)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Identifying Patient Access Barriers for Tumor Necrosis Factor Alpha Inhibitor Treatments in Rheumatoid Arthritis in Five Central Eastern European Countries
por: Inotai, András, et al.
Publicado: (2020)

Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis
por: Sugiyama, Masafumi, et al.
Publicado: (2022)

Induction of tumour necrosis factor receptor-expressing macrophages by interleukin-10 and macrophage colony-stimulating factor in rheumatoid arthritis
por: Takasugi, Koji, et al.
Publicado: (2006)

Response to Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis for Function and Pain is Affected by Rheumatoid Factor
por: Aberumand, Babak, et al.
Publicado: (2014)

An imprinted rheumatoid arthritis methylome signature reflects pathogenic phenotype
por: Whitaker, John W, et al.
Publicado: (2013)

Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis
por: Mandl, Peter, et al.
Publicado: (2020)

Tumor necrosis factor-alpha polymorphism and susceptibility to juvenile idiopathic arthritis
por: Bayraktar, S, et al.
Publicado: (2008)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
por: Leandro, Maria J
Publicado: (2009)

Cysteine-rich 61 (Cyr61): a biomarker reflecting disease activity in rheumatoid arthritis
por: Fan, Yong, et al.
Publicado: (2019)

T-Follicular Regulatory Cells: Potential Therapeutic Targets in Rheumatoid Arthritis
por: Ding, Tingting, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hr7c49eqn82t5q0eer2ump8e0t